http://adh2020.takedaoncologyvirtualexperience.com

Contact Information:

Marcus Brown
marcus.brown@takeda.com
612-388-1984

Virtual Exhibit Hall Home

At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer. We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.

NINLARO® (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Getting Started on NINLARO® (ixazomib) 

NINLARO® (ixazomib) National Webinar Invite 

NINLARO® (ixazomib) Dosing Guide 

Here2Assist Brochure